Dr. Carl Balezentis, President of Enzo Life Sciences commented, “The acquisition of this technology will further our new strategic initiatives and is expected to impact favorably on usage and sales of our proprietary array amplification kits.”
The technology, licensed from LBS Technologies, Inc., complements Enzo’s existing extensive line of gene amplification technology and product. Enzo’s license includes rights to six U.S. Patents. These patents, which are 5,021,335, 5,168,038, 5,545,522, 5,716,785, 5,891,636 and 6,291,170, all revolve around a particular form of RNA amplification. The technology associated with these patents facilitates increased levels of RNA present in cells to amounts that can produce gene expression patterns in microarrays and other applications.
Linear amplification technology involves a series of enzymatic reactions which produce a non-exponential amplification of RNA from relatively small amounts of RNA extracted from biopsies, laser-capture microdissection, and other tissue sources where the sample size is limited. Unlike exponential amplification techniques, such as RT-PCR, this technology maintains the relative ratios of the starting RNA population, thereby allowing for more accurate expression profile studies. Enzo has been developing related technology and products for a wide variety of amplification applications, and this agreement will allow the Company to provide more complete solutions to its research products customers.
About Enzo
Enzo Biochem and its subsidiaries (the Company) are engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis are sold to the life sciences market throughout the world. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary gene medicine for HIV-1 infection and its proprietary immune regulation medicines for hepatitis, uveitis, Crohn's disease, and for NASH and its associated metabolic syndrome. Pre-clinical research is being conducted on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes. The Company owns or licenses over 200 patents worldwide. For more information visit our website www.enzo.com.
Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.
###
Contacts;
For: Enzo Biochem, Inc.
Steve Anreder, 212-532-3232 Or Ed Lewis, CEOcast, Inc., 212-732-4300